Date: 6 AUGUST 2023

Your Name: ANDREA MESSORI

Manuscript Title: Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of

advanced non-small cell lung cancer: indirect comparison of randomized trials

Manuscript number (if known): CCO-23-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

			
-	Deciment on homograpic for	None	
5	Payment or honoraria for	None	
	lectures, presentations, speakers bureaus,		
	manuscript writing or		
	educational events		
5	Payment for expert	None	
	testimony		
7	Support for attending	None	
	meetings and/or travel		
3	Patents planned, issued or	None	
	pending		
9	Participation on a Data	None	
	Safety Monitoring Board or		
4.0	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society, committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
	Stock of Stock options		
L2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non- financial interests	None	
Dام	ase summarize the above co	onflict of interest in the	a following hov:
	ase sammanize the above to	Jimet of interest in the	, ronowing box.
	Authors AM declares no conf	lict of interests.	
Ple	ase place an "X" next to the	following statement t	o indicate your agreement:
		•	, 3
,	(I certify that I have answe	red every question and	d have not altered the wording of any of the questions or
 -		, qaoonon and	and the state of t

form.

Date: 6 AUGUST 2023

Your Name: MELANIA RIVANO

Manuscript Title: Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of

advanced non-small cell lung cancer: indirect comparison of randomized trials

Manuscript number (if known): CCO-23-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

Payment or honoraria for	None	
speakers bureaus, manuscript writing or educational events		
Payment for expert testimony	None	
Support for attending meetings and/or travel	None	
Patents planned, issued or pending	None	
Participation on a Data Safety Monitoring Board or Advisory Board	None	
Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None	
Stock or stock options	None	
Receipt of equipment, materials, drugs, medical writing, gifts or other services	None	
Other financial or non- financial interests	None	
ase summarize the above co	onflict of interest in the	e following box:
Authors MR declares no confl	ict of interests.	
	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or nonfinancial interests	lectures, presentations, speakers bureaus, manuscript writing or educational events Payment for expert testimony Support for attending meetings and/or travel Patents planned, issued or pending Participation on a Data Safety Monitoring Board or Advisory Board Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid Stock or stock options Receipt of equipment, materials, drugs, medical writing, gifts or other services Other financial or non- None

form.

Date: 6 AUGUST 2023

Your Name: MARCO CHIUMENTE

Manuscript Title: Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of

advanced non-small cell lung cancer: indirect comparison of randomized trials

Manuscript number (if known): CCO-23-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	SIFACT	I declare that I am full-time researcher of Sifact (Società Italiana di Farmacia Clinica e Terapia, Torino) and that I participated in this project in this role.
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	

4	Consulting fees	None
5	Payment or honoraria for	None
	lectures, presentations,	
	speakers bureaus, manuscript writing or	
	educational events	
6	Payment for expert	None
	testimony	
7	Support for attending	None
,	Support for attending meetings and/or travel	None
8	Patents planned, issued or	None
	pending	
9	Participation on a Data	None
	Safety Monitoring Board or	
	Advisory Board	
10	Leadership or fiduciary role	None
	in other board, society, committee or advocacy	
	group, paid or unpaid	
11	Stock or stock options	None
12	Receipt of equipment,	None
12	materials, drugs, medical	None
	writing, gifts or other	
	services	
13	Other financial or non- financial interests	None
	illiancial interests	
Ple		onflict of interest in the following box: is full-time researcher of Sifact (Società Italiana di Farmacia Clinica e Terapia, Torino)
	The declared that the is that the researcher of shade (società italiana ai l'armadia elimica e l'erapia, formo)	

Author MC declares that he is full-time researcher of Sifact (Società Italiana di Farmacia Clinica e Terapia, Torino) and that he participated in this project in this role.

Please place an "X" next to the following statement to indicate your agreement:

X I certify that I have answered every question and have not altered the wording of any of the questions on this form.	

Date: 6 AUGUST 2023

Your Name: DANIELE MENGATO

Manuscript Title: Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of

advanced non-small cell lung cancer: indirect comparison of randomized trials

Manuscript number (if known): CCO-23-26-CL

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	None	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None	
4	Consulting fees	None	

—.			
5	Payment or honoraria for	None	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or educational events		
-		None	
5	Payment for expert testimony	None	
	testimony		
7	Support for attending	None	
<i>'</i>	meetings and/or travel	None	
,	Data ata alama di Sassadan	News	
3	Patents planned, issued or pending	None	
	pending		·
)	Participation on a Data	None	
	Safety Monitoring Board or	INOTIC	
	Advisory Board		
10	Leadership or fiduciary role	None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	None	
.2	Receipt of equipment,	None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
.3	Other financial or non- financial interests	None	
Ple	ease summarize the above co	onflict of interest in the	following hox:
			,
	Authors DM declares no conf	lict of interests.	
Ple	ase place an "X" next to the	following statement t	o indicate your agreement:
	and place all A lient to the	statement t	o
,	V Loortifu that I have access	and avery greation and	d have not altered the wording of any of the guestions or
	vicerury uraci nave answe	red every question and	d have not altered the wording of any of the questions or

form.